Selecta Biosciences (SELB) vs. Its Rivals Critical Analysis
Selecta Biosciences (NASDAQ: SELB) is one of 290 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Selecta Biosciences to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, profitability, earnings, dividends and valuation.
Valuation & Earnings
This table compares Selecta Biosciences and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Selecta Biosciences||$8.08 million||-$36.21 million||-3.01|
|Selecta Biosciences Competitors||$290.27 million||$35.99 million||56.60|
This table compares Selecta Biosciences and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Selecta Biosciences Competitors||-5,400.85%||-161.62%||-35.75%|
This is a summary of recent ratings and target prices for Selecta Biosciences and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Selecta Biosciences Competitors||1148||3465||11979||242||2.67|
Selecta Biosciences presently has a consensus target price of $29.00, indicating a potential upside of 210.83%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.34%. Given Selecta Biosciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Selecta Biosciences is more favorable than its peers.
Institutional & Insider Ownership
54.4% of Selecta Biosciences shares are held by institutional investors. Comparatively, 49.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 41.9% of Selecta Biosciences shares are held by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Selecta Biosciences beats its peers on 7 of the 12 factors compared.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.